The differential diagnosis and interdisciplinary treatment of anal carcinoma
BACKGROUND: Anal carcinoma accounts for 2-4% of all cases of colorectal and anorectal carcinoma. Its peak incidence is from age 58 to age 64; women are affected somewhat more commonly than men. Its incidence has risen markedly in the past three decades.
METHODS: This article is based on a selective review of the literature, including the guidelines of the National Comprehensive Cancer Network and the European Society of Medical Oncology.
RESULTS: Anal carcinoma is often an incidental finding. About 85% of newly diagnosed cases are associated with an HPV infection with strain 16, 18, or 33. Radiochemotherapy with 5-fluorouracil and mitomycin C is the treatment of choice. The 5-year survival rate is 80-90%. Primary surgery with curative intent is indicated only for well-differentiated carcinoma of the anal margin (T1, N0). 10-30% of patients now undergo radical resection. The utility of endosonography and positron emission tomography for staging is debated and needs further study.
CONCLUSION: The treatment of patients with anal carcinoma requires a specialized multidisciplinary approach in accordance with the current evidence-based guidelines. The potential role of prophylactic vaccination against oncogenic types of HPV in the prevention of anal carcinoma merits further investigation.
Errataetall: |
CommentIn: Dtsch Arztebl Int. 2015 Oct 23;112(43):738. - PMID 26568181 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2015 |
---|---|
Erschienen: |
2015 |
Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
---|---|
Enthalten in: |
Deutsches Arzteblatt international - 112(2015), 14 vom: 03. Apr., Seite 243-9 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Raptis, Dimitrios [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 03.02.2016 Date Revised 13.11.2018 published: Print CommentIn: Dtsch Arztebl Int. 2015 Oct 23;112(43):738. - PMID 26568181 Citation Status MEDLINE |
---|
doi: |
10.3238/arztebl.2015.0243 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM248225774 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM248225774 | ||
003 | DE-627 | ||
005 | 20231224150937.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2015 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3238/arztebl.2015.0243 |2 doi | |
028 | 5 | 2 | |a pubmed24n0827.xml |
035 | |a (DE-627)NLM248225774 | ||
035 | |a (NLM)25891807 | ||
035 | |a (PII)arztebl.2015.0243 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Raptis, Dimitrios |e verfasserin |4 aut | |
245 | 1 | 4 | |a The differential diagnosis and interdisciplinary treatment of anal carcinoma |
264 | 1 | |c 2015 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.02.2016 | ||
500 | |a Date Revised 13.11.2018 | ||
500 | |a published: Print | ||
500 | |a CommentIn: Dtsch Arztebl Int. 2015 Oct 23;112(43):738. - PMID 26568181 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Anal carcinoma accounts for 2-4% of all cases of colorectal and anorectal carcinoma. Its peak incidence is from age 58 to age 64; women are affected somewhat more commonly than men. Its incidence has risen markedly in the past three decades | ||
520 | |a METHODS: This article is based on a selective review of the literature, including the guidelines of the National Comprehensive Cancer Network and the European Society of Medical Oncology | ||
520 | |a RESULTS: Anal carcinoma is often an incidental finding. About 85% of newly diagnosed cases are associated with an HPV infection with strain 16, 18, or 33. Radiochemotherapy with 5-fluorouracil and mitomycin C is the treatment of choice. The 5-year survival rate is 80-90%. Primary surgery with curative intent is indicated only for well-differentiated carcinoma of the anal margin (T1, N0). 10-30% of patients now undergo radical resection. The utility of endosonography and positron emission tomography for staging is debated and needs further study | ||
520 | |a CONCLUSION: The treatment of patients with anal carcinoma requires a specialized multidisciplinary approach in accordance with the current evidence-based guidelines. The potential role of prophylactic vaccination against oncogenic types of HPV in the prevention of anal carcinoma merits further investigation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
700 | 1 | |a Schneider, Ignaz |e verfasserin |4 aut | |
700 | 1 | |a Matzel, Klaus E |e verfasserin |4 aut | |
700 | 1 | |a Ott, Oliver |e verfasserin |4 aut | |
700 | 1 | |a Fietkau, Rainer |e verfasserin |4 aut | |
700 | 1 | |a Hohenberger, Werner |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Deutsches Arzteblatt international |d 2008 |g 112(2015), 14 vom: 03. Apr., Seite 243-9 |w (DE-627)NLM188802576 |x 1866-0452 |7 nnns |
773 | 1 | 8 | |g volume:112 |g year:2015 |g number:14 |g day:03 |g month:04 |g pages:243-9 |
856 | 4 | 0 | |u http://dx.doi.org/10.3238/arztebl.2015.0243 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 112 |j 2015 |e 14 |b 03 |c 04 |h 243-9 |